background
immunosuppress
therapi
renal
allograft
recipi
chang
substanti
sinc
introduct
monoclon
antibodi
basiliximab
hypothes
recent
improv
immunosuppress
treatment
may
reduc
incid
osteonecrosi
femor
head
onfh
studi
aim
investig
transit
chang
incid
ofnh
among
renal
transplant
recipi
mri
method
particip
compris
patient
undergon
renal
transplant
time
basiliximab
regular
use
institut
recent
group
patient
undergon
rt
past
group
compar
onfh
incid
two
group
evalu
risk
factor
onfh
includ
immunosuppress
calcineurin
inhibitor
basiliximab
andor
steroid
postop
renal
function
result
incid
onfh
lower
recent
group
past
group
p
recent
group
age
greater
abohuman
leukocyt
antigen
incompat
wors
steroid
dose
decreas
posttranspl
renal
function
improv
cumul
methylprednisolon
dose
postop
week
delay
graft
function
identifi
risk
factor
onfh
conclus
risk
onfh
renal
transplant
fallen
advent
regular
use
basiliximab
although
agent
appear
factor
directli
associ
incid
onfh
studi
design
clinic
prognost
studi
level
iii
case
control
studi
osteonecrosi
femor
head
onfh
well
recogn
musculoskelet
complic
renal
transplant
rt
advanc
immunosuppress
therapi
improv
posttranspl
renal
function
reduc
corticosteroid
dose
report
led
decreas
incid
onfh
howev
accord
recent
screen
studi
use
magnet
reson
imag
mri
incid
rang
infer
onfh
remain
signific
complic
among
renal
allograft
recipi
immunosuppress
therapi
renal
allograft
recipi
chang
substanti
sinc
introduct
monoclon
antibodi
basiliximab
simulect
novarti
east
hanov
nj
administ
induct
therapi
earli
postop
period
improv
postop
renal
function
report
decreas
dose
steroid
calcineurin
inhibitor
also
report
indic
rt
therefor
expand
includ
higherrisk
patient
older
age
increas
human
leukocyt
antigen
hla
mismatch
howev
impact
basiliximab
administr
incid
posttranspl
onfh
yet
determin
mri
screen
studi
conduct
sinc
introduct
hypothes
recent
improv
immunosuppress
treatment
may
reduc
incid
onfh
even
wider
indic
rt
purpos
present
studi
twofold
investig
transit
chang
incid
ofnh
among
renal
transplant
recipi
mri
investig
factor
relat
onfh
entir
cohort
ethic
review
board
institut
approv
design
studi
registr
number
recent
group
includ
patient
men
women
mean
deviat
age
year
rang
year
mean
bodi
mass
index
bmi
kgm
underw
mri
hip
rt
april
june
ie
period
basiliximab
regularli
use
period
patient
underw
rt
past
group
includ
patient
men
women
mean
age
year
mean
bmi
kg
undergon
rt
januari
march
ie
prior
regular
use
basiliximab
period
patient
underw
rt
signific
differ
rate
mri
screen
group
vs
p
chisquar
test
patient
notifi
report
incid
onfh
rt
benefit
risk
mri
possibl
treatment
option
given
opportun
object
mri
perform
month
rt
use
either
superconduct
magnet
system
signa
horizon
lx
gener
electr
medic
system
milwauke
wi
one
two
superconduct
magnet
system
shimadzu
kyoto
japan
achieva
aseri
philip
healthcar
amsterdam
netherland
osteonecrosi
defin
area
normal
intens
demarc
lowintens
band
imag
spinecho
imag
obtain
use
system
coron
sagitt
plane
follow
set
repetit
time
tr
ms
echo
time
te
ms
slice
thick
mm
spoil
gradientrecal
echo
puls
sequenc
obtain
use
system
coron
plane
follow
set
tr
ms
te
ms
flip
angl
slice
thick
mm
interslic
gap
follow
item
evalu
onfh
incid
patient
demograph
background
factor
includ
gender
age
bmi
abo
hla
incompat
durat
preoper
dialysi
type
renal
graft
livingcadaver
donor
preoper
immunosuppress
use
includ
calcium
inhibitor
cyclosporin
atacrolimu
administ
initi
time
hospit
discharg
concomit
basiliximab
administr
steroid
administr
week
rt
prednisolon
psl
methylprednisolon
mpsl
total
steroid
dose
convert
pslequival
dose
postop
renal
function
includ
delay
graft
function
dgf
blood
urea
nitrogen
bun
creatinin
cr
level
week
rt
acut
transplant
reject
durat
hospit
pslequival
dose
calcul
adjust
mpsl
dose
basi
antiinflammatori
potenc
use
convers
factor
acut
transplant
reject
diagnos
follow
increas
bun
increas
cr
level
compar
previou
sampl
daili
urinari
output
ml
diagnosi
biopsi
dgf
defin
patient
requir
hemodialysi
first
week
rt
compar
item
recent
past
group
use
mannewhitney
utest
chisquar
test
fisher
exact
probabl
test
statist
analys
addit
investig
factor
influenc
incid
onfh
entir
cohort
uniand
multivari
logist
regress
model
use
identifi
signific
risk
factor
onfh
entir
cohort
adjust
odd
ratio
predict
onfh
determin
factor
identifi
univari
logist
regress
analysi
spss
window
version
statist
softwar
spss
chicago
il
use
statist
analys
signific
level
appli
test
case
onfh
record
recent
group
confid
interv
ci
although
eight
case
onfh
record
past
group
ci
onesid
fisher
exact
probabl
test
p
intergroup
comparison
background
demograph
factor
reveal
signific
increas
age
bmi
number
patient
abo
hla
incompat
live
kidney
donor
recent
group
tabl
comparison
postop
immunosuppress
use
show
increas
frequenc
tacrolimu
use
increas
number
patient
concomit
use
basiliximab
decreas
mpsl
psl
total
steroid
dose
postop
week
recent
group
tabl
regardless
increas
risk
factor
rt
older
age
increas
number
abohlaincompat
transplant
among
patient
decreas
steroid
administr
improv
postop
renal
function
observ
recent
group
addit
signific
decreas
seen
number
case
dgf
concentr
bun
cr
week
transplant
incid
acut
transplant
reject
durat
hospit
time
tabl
overal
result
survey
risk
factor
onfh
accord
analysi
individu
factor
total
mpsl
dose
postop
week
total
steroid
dose
postop
week
dgf
identifi
signific
risk
factor
tabl
psl
administr
postop
week
risk
factor
perform
multivari
analysi
logist
regress
analysi
age
gender
total
mpsl
dose
postop
week
dgf
signific
risk
factor
onfh
total
mpsl
dose
postop
week
ci
p
dgf
ci
p
tabl
mpsl
dose
postop
week
select
risk
factor
rather
week
follow
adjust
valu
week
ci
p
week
ci
p
week
ci
p
mpsl
administr
week
show
highest
adjust
type
onfh
accord
japanes
investig
committe
classif
natur
cours
surgic
treatment
summar
tabl
improv
posttranspl
renal
function
reduct
corticosteroid
dose
may
led
decreas
incid
onfh
renal
graft
function
rt
improv
advanc
immunosuppress
agent
cyclosporin
tacrolimu
sever
immunosuppress
agent
includ
sirolimu
everolimu
mycophenol
mofetil
basiliximab
introduc
combin
cyclosporin
tacrolimu
also
improv
postop
renal
function
contrast
report
publish
influenc
new
immunosuppress
agent
incid
onfh
rt
basiliximab
monoclon
antibodi
strong
immunosuppress
agent
exert
effect
competit
antagon
administ
induct
therapi
earli
postop
period
conjunct
one
convent
immunosuppress
drug
decreas
incid
acut
transplant
reject
dgf
improv
surviv
transplant
kidney
report
decreas
steroid
calcineurin
inhibitor
dose
also
report
mark
chang
immunosuppress
treatment
postop
renal
function
may
reduc
incid
onfh
proport
onfh
patient
receiv
steroid
treatment
renal
transplant
reportedli
decreas
recent
accord
multicent
hospitalbas
sentinel
monitor
system
onfh
japan
although
reason
decreas
proport
onfh
patient
receiv
renal
transplant
remain
unclear
addit
small
number
report
sinc
describ
mri
screen
onfh
rt
impact
introduct
basiliximab
posttranspl
incid
onfh
yet
determin
therefor
investig
incid
onfh
sinc
advent
regular
basiliximab
use
found
postop
renal
graft
function
improv
mpsl
dose
incid
dgf
risk
factor
onfh
decreas
addit
incid
onfh
decreas
basiliximab
seem
like
indirectli
reduc
incid
onfh
reduc
incid
dgf
allow
reduct
mpsl
administr
three
main
limit
need
consid
interpret
result
present
studi
first
number
renal
transplant
recipi
use
basiliximab
might
small
evalu
effect
incid
onfh
number
patient
includ
previou
mri
screen
studi
rang
number
patient
present
studi
compar
number
studi
second
mri
screen
perform
rt
could
sure
onfh
present
prior
transplant
nevertheless
incid
onfh
studi
lower
previou
studi
evalu
use
mri
incid
presum
also
low
even
transplant
third
time
mri
screen
earlier
compar
mri
screen
studi
might
one
reason
incid
onfh
institut
lower
describ
report
perform
similar
period
encount
symptomat
case
onfh
mri
neg
month
rt
consid
incid
onfh
occur
month
rt
unlik
particularli
high
onfh
occur
patient
underw
rt
april
june
institut
despit
wider
indic
rt
highrisk
patient
older
age
sever
abo
hla
incompat
previou
mri
screen
studi
onfh
rt
perform
without
use
basiliximab
incid
onfh
rt
within
rang
although
downward
trend
observ
studi
mri
screen
studi
onfh
report
sinc
present
studi
show
lowest
incid
onfh
rt
among
relev
studi
tabl
elucid
risk
factor
onfh
rt
recipi
underw
mri
screen
institut
analyz
result
show
dgf
cumul
mpsl
administr
week
rt
signific
risk
factor
risk
factor
onfh
report
rt
includ
daili
oral
steroid
dose
bun
level
month
rt
accumul
steroid
dose
month
accumul
steroid
dose
week
ethnic
africanamerican
histori
periton
dialysi
reject
delay
graft
function
cyclosporin
administr
date
cumul
steroid
dose
week
postop
report
shortestterm
risk
factor
onfh
risk
factor
onfh
rt
present
studi
accord
past
find
result
suggest
onfh
occur
mostli
within
first
week
rt
suggest
import
control
postop
graft
function
reduc
cumul
mpsl
administr
first
week
rt
use
immunosuppress
agent
appropri
prevent
onfh
recent
metaanalysi
onfh
occurr
among
patient
take
corticosteroid
report
posit
associ
mean
daili
corticosteroid
dose
onfh
across
diagnos
includ
sever
acut
respiratori
syndrom
system
lupu
erythematosu
bone
marrow
transplant
renal
transplant
although
correl
mean
daili
corticosteroid
dose
onfh
incid
signific
among
renal
transplant
recipi
evid
signific
correl
cumul
corticosteroid
dose
incid
onfh
yet
provid
renal
transplant
recipi
daili
steroid
dose
gradual
taper
accord
immunosuppress
regimen
reflect
overal
pictur
steroid
treatment
use
mean
valu
daili
steroid
dose
difficult
addit
durat
steroid
treatment
overal
cumul
steroid
dose
vari
wide
among
renal
recipi
steroid
administr
onset
onfh
might
includ
regress
analysi
therefor
focus
correl
steroid
administr
includ
oral
steroid
administr
puls
steroid
therapi
week
renal
transplant
onset
onfh
month
risk
onfh
rt
fallen
sinc
advent
regular
basiliximab
use
although
agent
appear
factor
directli
associ
incid
onfh
factor
relat
onfh
incid
found
renal
graft
function
mpsl
administr
week
sinc
introduct
basiliximab
immunosuppress
therapi
chang
markedli
renal
graft
control
also
enhanc
may
led
decreas
incid
onfh
research
support
practic
research
project
rareintract
diseas
japan
agenc
medic
research
develop
ame
accord
icmj
criteria
ns
st
design
studi
mt
wrote
initi
draft
manuscript
ha
contribut
collect
interpret
data
assist
prepar
manuscript
literatur
data
search
analyz
mt
ha
author
contribut
data
collect
interpret
author
approv
final
version
submit
public
agre
account
aspect
work
none
procedur
perform
studi
involv
human
particip
accord
ethic
standard
institut
research
committe
declar
helsinki
later
amend
compar
ethic
standard
inform
consent
obtain
form
optout
websit
reject
exclud
